Endoscopic Detection of Early Neoplasia in Patients With Barrett's Esophagus

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

* The use of high resolution endoscopy (HRE), narrow band imaging (NBI) and chromoendoscopy increases the detection rates of Barrett's esophagus (BE) and early neoplasia. * Endoscopic mucosal resection (EMR) will improve the accuracy for detection of dysplasia/early neoplasia. Specific Aim 1 - To create a video-atlas of non-dysplastic and dysplastic/early neoplastic lesions in patients with BE. This will be used for training purposes and to assess learning curve associated with these new technologies. Specific Aim 2 - To create a standardized classification system for the mucosal and vascular patterns observed in patients with BE. Specific Aim 3 - To determine the interobserver agreement using the video-atlas for the mucosal and vascular patterns classification agreed upon. Specific Aim 4 - To determine the endoscopic detection rate of esophageal cancer or precancerous lesions removed during endoscopy. Specific Aim 5 - To determine the pathologic and clinical outcomes of patients undergoing EMR/ablation; including morbidity, mortality and complications of the procedure. Results to date (June 2008) : this study is active and open to enrollment. Currently 26 patients have enrolled in this study at the Kansas City VA medical center. In order to participate, patients must be eligible for care at the KCVA hospital.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18-80 years

• Patients must be able to provide written informed consent

• Patients referred for endoscopy for screening/surveillance of BE or for endoscopic treatment of BE with early mucosal neoplasia

Locations
United States
Missouri
Kansas city VA Medical center
RECRUITING
Kansas City
Contact Information
Primary
April Higbee, BN
April.Higbee@va.gov
8168614700
Time Frame
Start Date: 2007-05-15
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 150
Sponsors
Collaborators: Kansas City Veteran Affairs Medical Center
Leads: Midwest Biomedical Research Foundation

This content was sourced from clinicaltrials.gov